MedTrace Logo

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

NCT00802100 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2013-02-08

Study results available
· View outcomes & findings →

Summary

This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.

Conditions

Interventions

DRUG

Olanzapine

Daily tablets of 10 to 30 mg

DRUG

Perphenazine

Daily tablets of 8 to 24 mg

DRUG

Aripiprazole

Daily tablets of 10 to 30 mg

DRUG

Metformin

Daily tablets of 850 to 2550 mg

DRUG

Simvastatin

Daily tablets of 20 to 40 mg

DRUG

Benztropine

Daily tablets of 1 to 2 mg

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • Marvin Swartz, MD · Duke University

  • T. Scott Stroup, MD, MPH · University of North Carolina, Chapel Hill

  • Joseph P. McEvoy, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-09-30
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00802100 on ClinicalTrials.gov